CoVID-19 Vaccine Efficacy in Heart Transplant Recipients, a Single Center Experience
1Loyola University Medical Center, Maywood, IL, 2Microbiology and Immunology, Loyola University Chicago, Chicago, IL, 3Department of Public Health Sciences, Loyola University Chicago, Chicago, IL, 4Loyola Univ Medical Ctr, Maywood, IL
Meeting: 2022 American Transplant Congress
Abstract number: 242
Keywords: COVID-19, Heart transplant patients, Vaccination
Topic: Clinical Science » Heart » 63 - Heart and VADs: All Topics
Session Information
Session Name: Heart and VADs: All Topics II
Session Type: Rapid Fire Oral Abstract
Date: Monday, June 6, 2022
Session Time: 3:30pm-5:00pm
Presentation Time: 4:50pm-5:00pm
Location: Hynes Room 210
*Purpose: Transplant recipients have worse CoVID-19 survival compared to the general population, and thus are recommended to be vaccinated and boosted. Determinants of vaccination efficacy have not been well studied in heart transplant patients.
*Methods: This was a prospective study of heart transplant recipients vaccinated against SARS-CoV-2 with one of the 2-dose mRNA vaccine series. Antibodies (Ab) were quantified by anti-Spike ELISA pre- and post-vaccination. Clinical data was extracted from electronic medical records. Differences in Ab detection and timing of Abs were assessed for statistical significance using Fisher’s exact tests for categorical variables and t-tests for continuous variables.
*Results: Of the total 54 participants recruited from Jan 2021 to present, 6 patients were Ab positive prior to vaccination and 11 did not provide a pre-vaccination sample but were Ab positive post-vaccination. Almost half of participants (48%, n=26) received a booster 3rd dose. The mean age at vaccination was 58 ± 11, 20% (n=11) were female, 70% (n=38) were Caucasian, and median time since transplant was 4 years (interquartile range: 2-11 years). Of the 37 Ab-negative individuals enrolled, none developed detectable Abs after a single vaccine dose and only 9 (24%) developed Abs after the 2nd vaccine dose. Interestingly in this small group, 6/9 (66%) of participants had delayed seroconversion of approximately 3 months. Unexpectedly, hyperlipidemia was positively associated with a detectable antibody response (p = 0.05) after the 2nd dose. There was also a trend toward higher age (p=0.06) and BMI (p=0.08) being associated with lack of response to the 2-dose series. Importantly, of the 28 patients who had no Ab response to the 2-dose vaccination regimen, 11/17 (65%) became Ab positive after the booster, increasing the vaccine response rate in this pre-vaccine Ab-negative group to 20/37 (54%). Looking at the total cohort of 54 participants, the overall positivity rate regardless of antigen sources (i.e., including those previously infected or for whom no pre-vaccine sample is available) is 68.5% (37/54) with a trend suggesting that absence of Ab response may be associated with prednisone treatment (p=0.06).
*Conclusions: Heart transplant recipients exhibit a low response rate to the initial 2-dose mRNA vaccines (24%), but the 3rd dose induces a response in the majority of those who failed to respond to the 2-dose series increasing overall response to over 50%. Similar to observations in the general public, non-response tended to be associated with older age and higher BMI. However, further/larger studies are needed to identify key determinants of vaccine efficacy in this population to guide management.
To cite this abstract in AMA style:
Yu M, Sharmin SB, Joyce C, Pieters Z, DeSirkar S, Thomas M, Kim S, Bruno E, Liebo M, Heroux A, Clark N, Reid G, Uprichard S. CoVID-19 Vaccine Efficacy in Heart Transplant Recipients, a Single Center Experience [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/covid-19-vaccine-efficacy-in-heart-transplant-recipients-a-single-center-experience/. Accessed November 23, 2024.« Back to 2022 American Transplant Congress